Calcium Channel Blockers Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Type, By Application, By Distribution Channel, By Region & Competition, 2021-2031F

全球钙离子通道阻断剂市场预计将从 2025 年的 162.2 亿美元成长到 2031 年的 233.9 亿美元，复合年增长率为 6.29%。

这些药物透过抑制钙离子流入心肌细胞和动脉细胞，促进血管舒张，进而改善心臟的氧气输送。市场成长的主要驱动因素并非固定剂量复方製剂等短期趋势，而是慢性心血管疾病在全球日益加重的负担以及人口快速老化导致持续治疗管理需求不断增加。

儘管临床需求强劲，但主要品牌药专利到期却构成了一项重大障碍：价格低廉的学名药正在蚕食品牌药的收入来源。这种竞争压力阻碍了品牌药的财务扩张，儘管患者数量仍在持续成长。世界卫生组织（世卫组织）2025年发布的数据显示，到2024年，全球约有14亿人将患有高血压，凸显了该疾病的巨大规模，亟需有效的治疗方案。

市场驱动因素

全球高血压和心血管疾病盛行率的激增是钙离子通道阻断剂市场的主要驱动因素，也因此产生了对降血压药物治疗的迫切需求。随着这些疾病成为主要致病原因，医疗系统优先使用氨氯地平等药物来降低中风风险，导致处方量增加，对现有疗法的需求持续强劲。根据美国心臟协会 (AHA) 于 2025 年 1 月发布的《2025 年心血管和中风统计更新》，心血管疾病预计将导致全球约 1941 万人死亡，凸显了有效管理的重要性。此外，根据英国国家医疗服务体系 (NHS) 商业服务部门 2025 年 6 月报告，2024/25 年度氨氯地平的处方量为 3,970 万剂，仍然是英格兰处方量最大的药物之一。

由于老年人口的快速成长，市场成长正在进一步加速，因为老龄化与动脉粥状硬化和单纯收缩期高血压的进展密切相关。这种人口结构的变化需要长期持续用药，而老年人，尤其是在平均预期寿命不断延长的已开发地区，併发症风险较高，因此他们成为这些药物的主要消费群体。根据内务部2025年9月发布的公告，日本65岁以上人口占总人口的比例已达到创纪录的29.4%。这表明需要接受心血管疾病治疗的人群规模正在扩大。

市场挑战

主要品牌药专利的到期对全球钙离子通道阻断剂市场构成重大障碍，直接限制了其财务成长。一旦独家经销权到期，低成本学名药将大幅蚕食市场份额，削弱生产商的定价权，并导致现有重磅疗法的收入急剧下降。因此，学名药的涌入使治疗领域趋于同质化，降低了製药公司的利润率，使得整体市场估值难以与临床需求保持同步成长。

高血压的高发生率进一步加剧了收入下滑。虽然高发病率显着增加了处方笺量，但单位药品收入却呈下降趋势。根据美国心臟协会 (AHA) 2025 年的预测，届时美国约有 50% 的成年人将患有高血压。这些数据表明，儘管患者群体庞大，但由于大部分需求由低价学名药满足，而对高价值品牌药的需求有限，市场收入成长受到抑制。

市场趋势

随着医疗机构优先考虑简化治疗方法以提高患者依从性，固定剂量组合药物的日益普及正在改变市场格局。这一趋势包括将钙通道阻断剂和其他降血压药物组合成单片製剂的开发，旨在减轻用药负担并改善临床疗效。用于治疗早期高血压的三重组合药物的推出就是一个例子。根据 Medscape Medical News 2025 年 6 月报道，美国食品药物管理局(FDA)核准了一种新的固定剂量组合药物，该药物由氨氯地平、Telmisartan和吲达帕胺组成，详情见题为“FDA核准用于治疗高血压的三联组合药物”的报导。该药物有三种剂量规格，以满足患者的不同需求。

同时，学名药的快速上市正在加速市场活动。各公司正利用专利到期推出更具成本效益的替代药物。这一趋势导致简略新药申请（ANDA）的提交和核准激增，显着扩大了现有钙离子通道阻断剂疗法的可及性。这是因为各公司正积极透过非专利版本来强化其产品线。例如，根据《商业标准报》2025年8月报道，Zydus Life Sciences公司用于治疗心绞痛的盐酸地尔硫卓片获得了美国食品药物管理局（FDA）的最终核准。该药物瞄准了美国一个年销售额约1390万美元的特定细分市场。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球钙离子通道阻断剂市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 药物类型（二氢吡啶类、苯烷基胺类、苯并噻唑类）
  • 依应用领域（心绞痛、高血压、肥厚型心肌病、心律不整等）
  • 分销通路（网路药局、医院药局、零售药局）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美钙离子通道阻断剂市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲钙离子通道阻断剂市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区钙离子通道阻断剂市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲钙离子通道阻断剂市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美钙离子通道阻断剂市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球钙离子通道阻断剂市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bayer AG
• Sanofi Sa
• Pfizer Inc
• Lupin Pharmaceuticals, Inc.
• Searle Ltd
• Knoll Pharmaceuticals Co
• GlaxoSmithKline Plc.
• Aventis Inc
• AstraZeneca PLC
• Novartis AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Calcium Channel Blockers Market is projected to expand from USD 16.22 Billion in 2025 to USD 23.39 Billion by 2031, reflecting a compound annual growth rate of 6.29%. These pharmaceutical agents function by inhibiting the influx of calcium into cardiac and arterial cells, which facilitates blood vessel relaxation and enhances oxygen delivery to the heart. The market's growth is fundamentally supported by the rising global burden of chronic cardiovascular diseases and a rapidly aging population requiring consistent therapeutic management, drivers that are distinct from transient trends such as the shift toward fixed-dose combination therapies.

Despite robust clinical demand, the market encounters significant obstacles due to the expiration of patents for major branded drugs, enabling affordable generic alternatives to diminish branded revenue streams. This competitive pressure constrains financial expansion even as the patient population continues to increase. According to the World Health Organization, data released in 2025 indicated that approximately 1.4 billion individuals globally were living with hypertension in 2024, highlighting the massive scale of the condition that necessitates effective treatment solutions.

Market Driver

The surging global prevalence of hypertension and cardiovascular diseases serves as the primary catalyst for the calcium channel blockers market, creating an urgent need for antihypertensive pharmacotherapy. As these conditions become leading causes of morbidity, healthcare systems are prioritizing agents like amlodipine to lower stroke risks, resulting in elevated prescription volumes and sustained demand for established therapeutics. According to the American Heart Association's '2025 Heart Disease and Stroke Statistics Update' from January 2025, cardiovascular disease caused approximately 19.41 million deaths globally, emphasizing the critical need for effective management; furthermore, the NHS Business Services Authority reported in June 2025 that amlodipine remained a top prescribed medicine in England with 39.7 million items dispensed during 2024/25.

Market growth is further amplified by the rapid expansion of the geriatric population, as aging is intrinsically linked to increased arterial stiffness and isolated systolic hypertension. This demographic shift requires consistent, long-term medication regimens, positioning the elderly as the primary consumer base for these drugs, particularly given their susceptibility to comorbidities in developed regions with rising life expectancies. According to the Ministry of Internal Affairs and Communications of Japan in September 2025, the elderly population aged 65 and over reached a record 29.4% of the nation's total, demonstrating the expanding scale of the demographic requiring cardiovascular interventions.

Market Challenge

The expiration of patents for key branded drugs presents a substantial hurdle that directly restricts the financial growth of the Global Calcium Channel Blockers Market. When exclusive marketing rights cease, lower-cost generic alternatives seize significant market share, forcing a reduction in pricing power for manufacturers and leading to a sharp decline in revenue from established blockbuster therapies. Consequently, the overall market valuation struggles to grow at the same pace as clinical demand, as the influx of generics commoditizes the treatment landscape and erodes profit margins for original innovators.

This revenue erosion is exacerbated by the high prevalence of the condition, which generates substantial prescription volumes but yields diminishing returns per unit. According to the American Heart Association in 2025, nearly 50% of adults in the United States were estimated to have high blood pressure. This data highlights that while the patient base is extensive, the market's financial trajectory is suppressed because a significant portion of this demand is satisfied by low-cost generic agents rather than high-value branded formulations.

Market Trends

The increasing adoption of fixed-dose combination therapies is reshaping the market as healthcare providers prioritize simplified treatment regimens to enhance patient adherence. This trend involves the development of single-pill formulations that merge calcium channel blockers with other antihypertensive agents, thereby reducing pill burden and improving clinical outcomes, including the introduction of triple-combination therapies for initial hypertension treatment. According to Medscape Medical News in June 2025, the US FDA approved a novel fixed-dose combination of amlodipine, telmisartan, and indapamide, available in three dosage strengths to accommodate varying patient needs, as detailed in the article 'FDA Approves Triple Rx for Hypertension'.

Simultaneously, the accelerated commercialization of generic drug variants is intensifying market activity as manufacturers leverage patent expirations to introduce cost-effective alternatives. This trend is driving a surge in Abbreviated New Drug Application (ANDA) filings and approvals, significantly broadening access to established calcium channel blocker therapies as companies aggressively fortify their portfolios with generic versions. For instance, according to Business Standard in August 2025, Zydus Lifesciences received final USFDA approval for Diltiazem Hydrochloride tablets to treat angina, targeting a specific market segment that generated annual sales of approximately $13.9 million in the United States.

Key Market Players

• Bayer AG
• Sanofi Sa
• Pfizer Inc
• Lupin Pharmaceuticals, Inc.
• Searle Ltd
• Knoll Pharmaceuticals Co
• GlaxoSmithKline Plc.
• Aventis Inc
• AstraZeneca PLC
• Novartis AG

Report Scope

In this report, the Global Calcium Channel Blockers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Calcium Channel Blockers Market, By Drug Type

• Dihydropyridine
• Phenylalkylamine
• Benzothizepine

Calcium Channel Blockers Market, By Application

• Angina
• Hypertension
• Hypertrophic Cardiomyopathy
• Arrhythmia
• Others

Calcium Channel Blockers Market, By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Calcium Channel Blockers Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Calcium Channel Blockers Market.

Available Customizations:

Global Calcium Channel Blockers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Calcium Channel Blockers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Dihydropyridine, Phenylalkylamine, Benzothizepine)
  • 5.2.2. By Application (Angina, Hypertension, Hypertrophic Cardiomyopathy, Arrhythmia, Others)
  • 5.2.3. By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Calcium Channel Blockers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Calcium Channel Blockers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Calcium Channel Blockers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Calcium Channel Blockers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Calcium Channel Blockers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Calcium Channel Blockers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Calcium Channel Blockers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Calcium Channel Blockers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Calcium Channel Blockers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Calcium Channel Blockers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Calcium Channel Blockers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Calcium Channel Blockers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Calcium Channel Blockers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Calcium Channel Blockers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Calcium Channel Blockers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Calcium Channel Blockers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Calcium Channel Blockers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Calcium Channel Blockers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Calcium Channel Blockers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Calcium Channel Blockers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America Calcium Channel Blockers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Calcium Channel Blockers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Calcium Channel Blockers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Calcium Channel Blockers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Calcium Channel Blockers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi Sa
• 15.3. Pfizer Inc
• 15.4. Lupin Pharmaceuticals, Inc.
• 15.5. Searle Ltd
• 15.6. Knoll Pharmaceuticals Co
• 15.7. GlaxoSmithKline Plc.
• 15.8. Aventis Inc
• 15.9. AstraZeneca PLC
• 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer